Skip to content


    DEA Class; Rx

    Common Brand Names; Tri-Luma

    • Corticosteroids, Topical; 
    • Depigmenting Agents

    Hydroquinone: Inhibits melanocyte metabolic processes that produce melanin; incr excretion of melanin from melanocytes

    Fluocinolone: Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes

    Tretinoin: Follicular epithelium irritant


    Indicated for short-term treatment of moderate to severe melasma


    • Erythema (41-45%)
    • Desquamation (36-40%)
    • Burning (16-20%)
    • Dryness (11-15%)
    • Pruritis (11-15%)
    • Acne (5%)
    • Telangiectasia (3%)
    • Hyperesthesia (2%)
    • Rosacea (1%)
    • Vesicles (1%)
    • Xerostomia (1%)
    • Paresthesia (3%)

    Not indicated for maintenance treatment of melasma

    Avoid sun exposure

    Safety & efficacy of Tri-Luma in patients of skin types V and VI not studied. Excessive bleaching in pts with darker skin cannot be excluded.

    Safety & efficacy in treatment of hyperpigmentation conditions other than melasma of face not studied

    Contains sodium matabisulfite which may cause allergic-type reactions in susceptible pts.

    Hydroquinone may produce exogenous ochronosis (darkening of skin)- promptly discontinue if occurs

    Pregnancy Category: C

    Lactation: not known whether excreted in breast milk; use caution


    Apply to face qHS, at least 30 min before bedtime

    Wash face gently before application; rinse & pat dry

    Apply thin film of Tri-Luma to hyperpigmented area & 1/2 inch surrounding skin

    Do not use occlusive dressing



    • (0.01%/0.05%/4%)/30g